EP3487531A4 - Compositions and methods for treating frontotemporal dementia - Google Patents

Compositions and methods for treating frontotemporal dementia Download PDF

Info

Publication number
EP3487531A4
EP3487531A4 EP17831788.9A EP17831788A EP3487531A4 EP 3487531 A4 EP3487531 A4 EP 3487531A4 EP 17831788 A EP17831788 A EP 17831788A EP 3487531 A4 EP3487531 A4 EP 3487531A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
frontotemporal dementia
treating frontotemporal
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17831788.9A
Other languages
German (de)
French (fr)
Other versions
EP3487531A1 (en
Inventor
Sethu SANKARANARAYANAN
Ted Yednock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annexon Inc
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of EP3487531A1 publication Critical patent/EP3487531A1/en
Publication of EP3487531A4 publication Critical patent/EP3487531A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17831788.9A 2016-07-19 2017-07-19 Compositions and methods for treating frontotemporal dementia Withdrawn EP3487531A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364013P 2016-07-19 2016-07-19
PCT/US2017/042846 WO2018017711A1 (en) 2016-07-19 2017-07-19 Compositions and methods for treating frontotemporal dementia

Publications (2)

Publication Number Publication Date
EP3487531A1 EP3487531A1 (en) 2019-05-29
EP3487531A4 true EP3487531A4 (en) 2020-03-25

Family

ID=60992917

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17831788.9A Withdrawn EP3487531A4 (en) 2016-07-19 2017-07-19 Compositions and methods for treating frontotemporal dementia

Country Status (6)

Country Link
EP (1) EP3487531A4 (en)
AU (1) AU2017299579A1 (en)
CA (1) CA3030872A1 (en)
IL (1) IL264167A (en)
SG (1) SG11201900123TA (en)
WO (1) WO2018017711A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006507A1 (en) 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
SG11201803703UA (en) * 2015-11-24 2018-06-28 Annexon Inc Anti-complement factor c1q fab fragments and uses thereof
CN108159421B (en) * 2018-02-05 2021-05-18 苏州大学 Application of phosphatidylserine blocking agent in preparation of medicine for treating diseases related to platelet quantity reduction
JP7499760B2 (en) * 2018-11-02 2024-06-14 アネクソン，インコーポレーテッド Compositions and methods for treating brain injury
IL300059A (en) 2020-07-23 2023-03-01 Othair Prothena Ltd Anti-abeta antibodies
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066744A2 (en) * 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
WO2016073685A1 (en) * 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9480658B2 (en) * 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) * 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
WO2015006507A1 (en) * 2013-07-09 2015-01-15 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066744A2 (en) * 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
WO2016073685A1 (en) * 2014-11-05 2016-05-12 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LUI HANSEN ET AL: "Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation", CELL, ELSEVIER, AMSTERDAM, NL, vol. 165, no. 4, 21 April 2016 (2016-04-21), pages 921 - 935, XP029530775, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2016.04.001 *
S. K. SINGHRAO ET AL: "Role of complement in the aetiology of Pick's disease?", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1 May 1996 (1996-05-01), pages 578 - 593, XP055665408, Retrieved from the Internet <URL:https://academic.oup.com/jnen/article-pdf/55/5/578/8276203/55-5-578.pdf> [retrieved on 20200205] *
See also references of WO2018017711A1 *
TSAI RICHARD M ET AL: "Treatment of Frontotemporal Dementia", CURRENT TREATMENT OPTIONS IN NEUROLOGY, SPRINGER US, BOSTON, vol. 16, no. 11, 21 September 2014 (2014-09-21), pages 1 - 14, XP035395075, ISSN: 1092-8480, [retrieved on 20140921], DOI: 10.1007/S11940-014-0319-0 *

Also Published As

Publication number Publication date
WO2018017711A1 (en) 2018-01-25
IL264167A (en) 2019-02-28
CA3030872A1 (en) 2018-01-25
SG11201900123TA (en) 2019-02-27
AU2017299579A1 (en) 2019-01-24
EP3487531A1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
EP3423109A4 (en) Therapy for frontotemporal dementia
EP3206494A4 (en) Compositions and methods for treating cns disorders
EP3206493A4 (en) Compositions and methods for treating cns disorders
EP3224269A4 (en) Compositions and methods for treating cns disorders
EP3405577B8 (en) Compositions and methods for inhibiting factor d
EP3490582A4 (en) Methods and compositions for treating myelofibrosis
EP3250210A4 (en) Compositions and methods for treating cns disorders
EP3302379A4 (en) Compositions and methods for treating pterygium
EP3458158A4 (en) Compositions and methods for treating eczema
EP3277270A4 (en) Compositions and methods for treating anemia
EP3408344A4 (en) Well treatment methods and compositions
EP3209298A4 (en) Compositions and methods for treating insomnia
EP3442543A4 (en) Compositions and methods for neuralgenesis
EP3220906A4 (en) Compositions and methods for treating lysosomal disorders
EP3487531A4 (en) Compositions and methods for treating frontotemporal dementia
EP3189036A4 (en) Compositions and methods for treating proliferation disorders
EP3458079A4 (en) Compositions and methods for treating acne
EP3280420A4 (en) Compositions and methods for treating cns disorders
EP3405191A4 (en) Methods and compositions for treating hyperhidrosis
EP3368048A4 (en) Methods and compositions for the treatment of amyloidosis
EP3334710A4 (en) Compositions and methods for treating and preventing neurodegenerative disorders
EP3313387A4 (en) Methods and compositions for treating neurodegenerative disorders
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders
EP3445369A4 (en) Compositions and methods for treating dementia
EP3432913A4 (en) Methods and compositions for treating atherosclerosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20190219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20200215BHEP

Ipc: G01N 33/53 20060101ALI20200215BHEP

Ipc: A61P 25/00 20060101ALI20200215BHEP

Ipc: A61K 49/16 20060101ALI20200215BHEP

Ipc: G01N 33/532 20060101ALI20200215BHEP

Ipc: C07K 16/18 20060101ALI20200215BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20201125